Clinical Trial: NCT05602363
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Status:
RECRUITINGPhase:
Phase 1| Lead Sponsor: | Carna Biosciences, Inc. |
| Information Provided By: | Carna Biosciences, Inc. |
| Last Update Posted: | 2025-12-10 |
Study Overview
Brief Summary
This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.
Official Title
A Phase 1b Study of Oral AS-1763 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Conditions
B-cell Malignancy, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
Intervention / Treatment
- Drug: Docirbrutinib
Other Study ID Numbers
- C1763102
Start Date (Actual)
2023-08-01
Primary Completion Date (Estimated)
2027-09
Study Completion Date (Estimated)
2027-09
Enrollment (Estimated)
120
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | Carna Biosciences, Inc. |
| Information Provided By: | Carna Biosciences, Inc. |
| Last Update Posted: | 2025-12-10 |
Study Overview
Brief Summary
This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.
Official Title
A Phase 1b Study of Oral AS-1763 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Conditions
B-cell Malignancy, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
Intervention / Treatment
- Drug: Docirbrutinib
Other Study ID Numbers
- C1763102
Start Date (Actual)
2023-08-01
Primary Completion Date (Estimated)
2027-09
Study Completion Date (Estimated)
2027-09
Enrollment (Estimated)
120
Study Type
Interventional
Phase
Phase 1